ABSTRACT
Importance Evidence regarding audiovestibular adverse events post COVID-19 vaccination to date has been inconclusive regarding a potential etiological association. This study used a multi-data source approach to assess incidence of these events following COVID-19 vaccination.
Objective To determine if there was an increase in audiovestibular adverse events following COVID-19 vaccination in South-eastern Australia during January 2021 – March 2023.
Design Retrospective observational analysis of spontaneous reports of audiovestibular events to a statewide vaccine safety surveillance service, SAEFVIC, as well as accompanying self-controlled case series (SCCS) analysis using general practice data collected via the POpulation Level Analysis and Reporting (POLAR) tool with permission from Primary Health Networks (PHNs) as the de-identified dataset owners in Victoria and New South Wales.
Setting Victoria and New South Wales (NSW), Australia.
Participants Victorians who spontaneously reported an audiovestibular-related symptom or diagnosis to SAEFVIC, and people in Victoria and NSW who presented to a POLAR GP registered practice with a new audiovestibular diagnosis.
Exposures COVID-19 vaccination with adenovirus vector, mRNA or protein-subunit vaccine.
Outcomes and Measures In SAEFVIC, audiovestibular events of interest were ascertained through searching key words in the vaccine safety database. Reporting rates were calculated and compared per 100,000 COVID-19 vaccine doses administered and recorded in the Australian Immunisation Register (AIR). Audiovestibular presentations of interest were isolated from the general practice dataset aggregated by POLAR, by searching for relevant SNOMED CT codes. Similarly, relative incidence (RI) was calculated for all COVID-19 vaccine types.
Results This study demonstrates an increase in general practice presentations of vertigo following mRNA vaccines (RI= 1.40 P <.001), and tinnitus following both the adenovirus vector and mRNA vaccines (RI= 2.25, P <.001 and 1.53, P <.001 respectively). There was no increase in hearing loss following any COVID-19 vaccinations.
Conclusions and Relevance This is the first study that demonstrates an increase in audiovestibular presentations following COVID-19 vaccination, in particular, vertigo and tinnitus. Healthcare providers and vaccinees should be alert to potential audiovestibular complaints after COVID-19 vaccination. Our analysis highlights the importance of using large real-world datasets to gather reliable evidence for public health decision making.
KEY POINTS Question: Is there an increase in audiovestibular adverse events after COVID-19 vaccination (adenovirus vector [AstraZeneca’s Vaxzervria® ChadOx1-S], mRNA [Pfizer-BioNTech’s Comirnaty® BNT162b2 and Moderna’s Spikevax®] or protein-subunit [Novavax’s Nuvaxovid®])?
Findings: This Australian study using spontaneous surveillance reports and large-scale general practice data, found an increase in incidence related to vertigo following mRNA vaccines (Relative Incidence = 1.40, P <.001), and tinnitus following both adenovirus vector and mRNA vaccines (Relative Incidence = 2.25, P <.001 and 1.53,P <.001 respectively). No increase in hearing loss following vaccination was observed.
Meaning: Healthcare providers and vaccinees should be alert to potential audiovestibular complaints following COVID-19 vaccination.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
SAEFVIC, is funded by the Department of Health, Victoria for provision of state-wide vaccine safety services including continuous improvement in methods for vaccine vigilance and investigation of vaccine safety concerns.The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Access to SAEFVIC data conforms to the function as public health vaccine safety surveillance approved by the Royal Childrens Hospital Health Research Ethics Committee as a registered database 36219. The POLAR platform has ethics approval for collection, transfer and storage of general practice data (RACGP NREEC Protocol ID-17-008) Ethics approval for use of general practice data collected and processed by POLAR for this project was provided by Monash Human Research Ethics Committee [RES-18-0000-232A].
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Overall findings and results remain the same. The body of the manuscript has been revised for improved readability.
Data Availability
The datasets analysed for the current study are not publicly available.
